Avendus Future Leaders Invests Rs 3 Billion in Aragen Life Sciences
ECONOMY & POLICY

Avendus Future Leaders Invests Rs 3 Billion in Aragen Life Sciences

Aragen Life Sciences, a contract research, development, and manufacturing organisation (CRDMO), has received a Rs 3 billion investment from the Avendus Future Leaders Fund (FLF), a private equity fund managed by the Avendus Group, along with SBI Life Insurance. This investment comes out of Avendus’ third fund, which marks the fund’s second investment, the first being its investment in La Renon Healthcare earlier this year. 
Aragen, established in 2001, is primarily focused on developing innovative pharmaceuticals, though in recent years has started to develop digital and AI technologies. It also offers R&D services for manufacturing. 
Ritesh Chandra, Managing Partner, Avendus FLF, said that the investment underscores their belief in the company’s long‑term growth prospects of the CRDMO market in India and specifically Aragen’s ability to capture the market as well as the market for global pharmaceuticals. He remarked that the CRDMO industry is growing at a rate of 16 per cent, and that India will wield a greater share of this market over the coming years. India’s current share of the global market is 8 per cent, and Chandra expects that number to increase to 14 per cent.
With two investments in the healthcare sector under their belt, Avendus is now seeking investment opportunities in the electronics manufacturing and engineering space. 

Aragen Life Sciences, a contract research, development, and manufacturing organisation (CRDMO), has received a Rs 3 billion investment from the Avendus Future Leaders Fund (FLF), a private equity fund managed by the Avendus Group, along with SBI Life Insurance. This investment comes out of Avendus’ third fund, which marks the fund’s second investment, the first being its investment in La Renon Healthcare earlier this year. Aragen, established in 2001, is primarily focused on developing innovative pharmaceuticals, though in recent years has started to develop digital and AI technologies. It also offers R&D services for manufacturing. Ritesh Chandra, Managing Partner, Avendus FLF, said that the investment underscores their belief in the company’s long‑term growth prospects of the CRDMO market in India and specifically Aragen’s ability to capture the market as well as the market for global pharmaceuticals. He remarked that the CRDMO industry is growing at a rate of 16 per cent, and that India will wield a greater share of this market over the coming years. India’s current share of the global market is 8 per cent, and Chandra expects that number to increase to 14 per cent.With two investments in the healthcare sector under their belt, Avendus is now seeking investment opportunities in the electronics manufacturing and engineering space. 

Related Stories

Gold Stories

Next Story
Resources

Schindler named among Forbes’ World’s Best Employers 2026

Schindler has been named among Forbes’ World’s Best Employers 2026, a global ranking recognising companies for their workplace environments.Compiled by Forbes in partnership with Statista, the ranking is based on independent employee feedback, including whether employees would recommend their organisation to friends and family.The company said the recognition reflected its focus on creating a workplace where employees can develop their expertise and build careers. ..

Next Story
Infrastructure Urban

India needs an export-execution mindset: Vishesh Jain

Interview with Vishesh Jain, Founder & CEO, EximpleWhat gaps in India’s global trade ecosystem led you to build Eximple, and what problem did you see businesses struggling with most?Eximple came out of a problem that all three founders had seen from different choke points in the trade ecosystem. India has millions of MSMEs and manufacturers, and many of them can make products that are genuinely competitive on quality. Yet only a small fraction is able to build meaningful international businesses. In our experience, the gap is usually not manufacturing capability; it is the ability to exe..

Next Story
Building Material

Nuvoco reports 13.5% revenue growth in Q2 FY27

Nuvoco Vistas Corp. Ltd. reported consolidated revenue of Rs 27.9 billion for Q2 FY27, up 13.5% year on year. Cement sales volume rose 9% to 4.7 million tonnes (MMT), while EBITDA increased 11% to Rs 4.11 billion.The company said it began its cement operations in 2014 with a 2.3 MMT per annum (MMTPA) operation at Nimbol. It now aims to reach 35 MMTPA of cement capacity by FY28, nearly 15 times its initial capacity. Its portfolio spans cement, ready-mix concrete and modern building materials.On sustainability and cost efficiency, Nuvoco partnered with CleanMax for a 46.4 MW wind-solar hybrid re..

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement

SPECIAL OFFER
QR Code